delgocitinib delgocitinib delgocitinib (brand name corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. delgocitinib was developed by japan tobacco and approved in japan for the treatment of atopic dermatitis. in the united states, delgocitinib is in phase iii clinical trials and the food and drug administration has granted delgocitinib fast track designation for topical treatment of adults with moderate to severe chronic hand eczema. delgocitinibclinical datatrade namescorectimother namesjte-052; jte-052aatc codenonelegal statuslegal status rx-only in japan identifiers iupac name 3-pyrimidin-4-yl)-1,7-diazaspirooctan-1-yl]-3-oxopropanenitrile cas number1263774-59-9pubchem cid50914062drugbankdb16133chemspider59718502unii9l0q8kk220keggd11046chemical and physical dataformulac16h18n6omolar mass310.361 g·mol−13d model (jsmol)interactive image smiles c1cn(c(=o)cc#n)12ccn(c1ncnc3ccc13)c2 inchi inchi=1s/c16h18n6o/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11h,2,4,7-9h2,1h3,(h,18,19,20)/t11-,16-/m0/s1key:lowwyyzbznspdt-zbegnznmsa-n delgocitinib works by blocking activation of the jak-stat signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.